Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
What Patients Evaluating AOD 9604 Typically Report Timeline to first changes: Most published protocols note 4 to 6 weeks before body composition changes become measurable Areas of change: Visceral and subcutaneous fat reduction, with particular effect reported in the abdominal region in some subjects Energy and recovery: Some participants in clinical and investigational settings report improved energy and exercise recovery, though this is not a primary mechanism of the peptide What it is not: AOD 9604 does not cause rapid dramatic weight loss the way GLP-1 medications can in the first few months
Preclinical euglycaemic clamp data showed no impairment of insulin sensitivity at therapeutic doses
5-Amino-1MQ is an oral NNMT (nicotinamide N-methyltransferase) inhibitor that works by blocking an enzyme that depletes cellular NAD+ and SAM
Are you a pet owner
Contact your prescribing provider promptly if you experience unexpected or concerning symptoms
